Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics

Table 3 Change of disease activity using the second JAK inhibitor at 6-month

	Baseline	6-month	P value^a
Number of patients at assessment, n (%)	32 (100.0)	27 (84.4)	N/A
TJC	10.0 (6.0, 18.0)	0.0 (0.0, 2.0)	< 0.001
SJC	6.0 (4.0, 12.0)	0.0 (0.0, 0.0)	< 0.001
VAS	85.0 (80.0, 90.0)	30.0 (30.0, 30.0)	< 0.001
ESR, mm/h	52.0 (12.0, 69.0)	30.0 (24.0, 46.0)	0.100
CRP, mg/dL	1.01 (0.10, 2.68)	0.38 (0.13, 1.23)	0.026
DAS28-ESR	5.84 (5.41, 6.30)	3.28 (2.81, 3.89)	< 0.001
DAS28-CRP	5.48 (4.75, 5.94)	2.34 (1.78, 3.10)	< 0.001

^aThe P value of Wilcoxon signed rank test, which included 27 patients who had their disease activity assessed at both baseline and 6-month
JAK, Janus kinase; TJC, Tender joint count; SJC, Swollen joint count; VAS, Visual analogue scale; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, Disease activity score 28

ISSN: 2523-3106